While the Trump administration considers whether to reschedule cannabis from a Schedule I to a Schedule III drug, another plant is under increased scrutiny. Kratom, a tropical tree native to Southeast Asia, contains leaves with compounds that can produce stimulant-like effects in low doses and opioid-like effects in higher doses. Those calling for greater regulation of kratom products argue that its compounds pose a threat to public health, with significant potential for abuse and strong pharmacological effects, especially from concentrated or synthetic versions of the compound. Advocates for the plant cite the benefits of kratom as an alternative to opioids for managing pain. In a new analysis, Rockefeller Institute Director of Operations and Fellow Heather Trela outlines the patchwork of regulations that have sprung up across state and local governments in the absence of federal action. Continue Reading... |
